ApolloBio licenses Tocagen's immunotherapy

Tocagen Inc. (NASDAQ:TOCA) granted ApolloBio Corp. (NEEQ:430187) exclusive rights to develop and commercialize vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) in Taiwan and China, including Hong Kong and Macau, to treat high grade glioma (HGG).

Tocagen will receive an upfront payment of $16 million and is eligible for $4 million in near-term milestones plus up to $111 million in additional development and commercialization milestones, plus low double-digit royalties based on net sales...